Orexo´s Nomination Committee for the Annual General Meeting 2024
Comunicato Precedente
Comunicato Successivo
The Nomination Committee's proposals will be presented in the Notice of the AGM and on Orexo's website, www.orexo.com. Shareholders who want to submit proposals to the Nomination Committee can do this by sending an e-mail to ir@orexo.com (subject "Nomination Committee") at latest February 24, 2024.
Orexo AB (publ.)
Orexo AB (publ.)
Lena Wange, IR & Communications Director
Tel: +46 (0)18 780 88 00
E-mail: ir@orexo.com
About Orexo
Orexo is a Swedish pharmaceutical company with over 25 years of experience developing improved pharmaceuticals based on proprietary formulation technologies that meet large medical needs. On the US market, Orexo provides innovative treatment solutions for patients suffering from opioid use disorder and adjacent diseases. Products targeting other therapeutic areas are developed and commercialized worldwide with leading partners. Total net sales in 2022 amounted to SEK 624 million, and the number of employees to 126. Orexo is listed on Nasdaq Stockholm's main list and is available as an ADR on OTCQX (ORXOY) in the US.
For more information about Orexo please visit www.orexo.com. You can also follow X, (former Twitter), LinkedIn, and YouTube.
[1] The Danish Labour Market Supplementary Pension
[2] Third Dot´s shareholding in Orexo is registered in a foreign nominee's name, but is confirmed by Euroclear via voting right registration ahead of the extraordinary general meeting on
October 26, 2023, and amounted to 705 421 shares
The information was submitted for publication at 5 pm CET on October 26, 2023.
The following files are available for download:
View original content:https://www.prnewswire.co.uk/news-releases/orexos-nomination-committee-for-the-annual-general-meeting-2024-301969003.html
Ufficio Stampa
PR Newswire (Leggi tutti i comunicati)
209 - 215 Blackfriars Road
LONDON United Kingdom
